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When working with hot mix asphalt, road pavers are exposed to polycyclic aromatic hydrocarbons
(PAHs) through the inhalation of vapors and particulate matter (PM) and through dermal contact
with PM and contaminated surfaces. Several PAHs with four to six rings are potent carcinogens
which reside in these particulate emissions. Since urinary biomarkers of large PAHs are rarely de-
tectable in asphalt workers, attention has focused upon urinary levels of the more volatile and abun-
dant two-ring and three-ring PAHs as potential biomarkers of PAH exposure. Here, we compare
levels of particulate polycyclic aromatic compounds (P-PACs, a group of aromatic hydrocarbons
containing PAHs and heterocyclic compounds with four or more rings) in air and dermal patch sam-
ples from 20 road pavers to the corresponding urinary levels of naphthalene (U-Nap) (two rings),
phenanthrene (U-Phe) (three rings), monohydroxylated metabolites of naphthalene (OH-Nap)
and phenanthrene (OH-Phe), and 1-hydroxypyrene (OH-Pyr) (four rings), the most widely used bio-
markerof PAH exposure. Foreach worker, daily breathing-zone air (n 5 55) and dermal patch sam-
ples (n 5 56) were collected on three consecutive workdays along with postshift, bedtime, and
morning urine samples (n 5 149). Measured levels of P-PACs and the urinary analytes were used
to statistically model exposure–biomarker relationships while controlling for urinary creatinine,
smoking status, age, body mass index, and the timing of urine sampling. Levels of OH-Phe in urine
collected postshift, at bedtime, and the following morning were all significantly associated with levels
of P-PACs in air and dermal patch samples. For U-Nap, U-Phe, and OH-Pyr, both air and dermal
patch measurements of P-PACs were significant predictors of postshift urine levels, and dermal patch
measurements were significant predictors of bedtime urine levels (all three analytes) and morning
urine levels (U-Nap and OH-Pyr only). Significant effects of creatinine concentration were observed
for all analytes, and modest effects of smoking status and body mass index were observed for U-Phe
and OH-Pyr, respectively. Levels of OH-Nap were not associated with P-PAC measurements in air or
dermal patch samples but were significantly affected by smoking status, age, dayof sample collection,
and urinary creatinine. We conclude that U-Nap, U-Phe, OH-Phe, and OH-Pyr can be used as bio-
markers of exposure to particulate asphalt emissions, with OH-Phe being the most promising can-
didate. Indications that levels of U-Nap, U-Phe, and OH-Pyr were significantly associated with
dermal patch measurements well into the evening after a given work shift, combined with the small
ratios of within-person variance components to between-person variance components at bedtime,
suggest that bedtime measurements may be useful for investigating dermal PAH exposures.
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Asphalt (also known as bitumen) is a highly viscous
petroleum product that, when combined with addi-
tional materials (e.g. coal tar and gravel) to form
hot mix asphalt, is commonly used for paving roads.
While the chemical composition of asphalt varies ac-
cording to the source of petroleum and other ingre-
dients, constituents of asphalt include a complex
array of hydrocarbons (NIOSH, 2000). Of these,
studies of asphalt-exposed workers have focused pri-
marily upon the polycyclic aromatic hydrocarbons
(PAHs), a group of fused-ring aromatic compounds,
which includes several carcinogenic forms (IARC,
1987). Levels of PAHs in hot mix asphalt can vary
depending upon the source of raw materials and
whether coal tar was used in its production (Burstyn
and Kromhout, 2000; Burstyn et al., 2002).
During application of hot mix asphalt, workers are
exposed to PAHs through the inhalation of asphalt
vapor and fumes [condensed vapor in the liquid
and solid form, reported here as particulate matter
(PM)] and through dermal contact with PM via depo-
sition or direct contact with contaminated surfaces.
The vapor-phase emissions from hot mix asphalt
generally contain the smaller and more volatile PAHs
ranging in size from two to four rings [e.g. naphtha-
lene (Nap), phenanthrene (Phe), and pyrene (Pyr)],
whereas the particulates generally contain the larger
four to six rings species (e.g. chrysene, benzo(a)py-
rene, and benzo(g,h,i)perylene). Because the particu-
lates from hot mix asphalt contain the most
carcinogenic PAHs, health professionals are primar-
ily concerned about asphalt workers’ exposures to
PM via inhalation and dermal contact.
Although epidemiological studies point to in-
creased cancer risks among asphalt workers that are
likely related to PAH exposures (Partanen and
Boffetta, 1994; Boffetta et al., 1997; Hooiveld
et al., 2002; Boffetta et al., 2003a,b; Burstyn et al.,
2003; Randem et al., 2004; Burstyn et al., 2007),
the quantitative relationship between exposures to
asphalt chemicals and cancer risk is uncertain
(Chiazze et al., 1991; NIOSH, 2000). This uncer-
tainty stems largely from difficulties in assessing ex-
posures to asphalt emissions, particularly the PAH
content, via mixed routes (i.e. air and dermal contact,
as well as ingestion) and physical forms (i.e. vapors
and particulates). To address this uncertainty, previous
investigations have quantified asphalt exposures us-
ing both air samples and dermal patch samples to
gauge the amounts of PAHs potentially inhaled and
deposited on the skin (Jongeneelen et al., 1988;
McClean et al., 2004a; Väänänen et al., 2005).
Analytes included specific PAHs as well as several
nonspecific measures of PAH exposure, including
PM, benzene-soluble PM, and polycyclic aromatic
compounds (PACs, a group of aromatic hydrocarbons
containing primarily four to six ring PAHs and het-
erocyclic compounds). Urinary biomarkers have also
been used to assess exposures and internal doses of
PAHs in asphalt-exposed workers. Urinary levels of
unmetabolized PAHs and of monohydroxylated
PAH metabolites, notably those of Nap, Phe, and
Pyr, have been associated with airborne and dermal
exposures to PAHs in asphalt-exposed populations
(Väänänen et al., 2003; McClean et al., 2004b;
Campo et al., 2006a,b; Väänänen et al., 2006; Buratti
et al., 2007). (These urinary analytes are often con-
sidered in PAH biomonitoring studies because they
are much more abundant than urinary metabolites
of the larger, more carcinogenic PAH species).
However, only a few studies have reported concen-
trations of multiple urinary PAH biomarkers and
the corresponding levels of PAHs or PACs in air
and on dermal patch samples (Väänänen et al.,
2005; Väänänen et al., 2006).
In a study involving 20 road pavers who worked
with hot mix asphalt, PACs were measured in air
samples and on dermal patches (McClean et al.,
2004a). Levels of the PACs varied significantly ac-
cording to the specific tasks performed by the pavers,
and also differed between air measurements and der-
mal patch measurements, suggesting that PAC expo-
sures were differentially expressed regarding the air
and skin (McClean et al., 2004a). In a follow-up
investigation, these same workers were further
examined using urinary OH-Pyr as a biomarker of
exposure to asphalt emissions (McClean et al.,
2004b). The authors concluded that the effect of der-
mal exposure to asphalt emissions on OH-Pyr levels
was eight times that of inhalation exposure and that
the effect of inhalation exposure was more apparent
immediately after the work shift, while the effect of
dermal exposure was more apparent during the pe-
riod of 8–16 h after the work shift (McClean et al.,
2004b).
More recently, urinary levels of Nap and Phe, and
of monohydroxylated metabolites of Nap, Phe, and
Pyr, were analyzed in archived urine from the same
20 road pavers (Sobus et al., 2009a). Results showed
that urinary biomarker measurements significantly
varied by work assignment, as had been observed
for PAC measurements in the same workers
(McClean et al., 2004a; Sobus et al., 2009a). Thus,
the results indicated that urinary biomarkers of
Nap, Phe, and Pyr may be suitable exposure surro-
gates for hot mix asphalt emissions (Sobus et al.,
2009a). The purpose of the current investigation is
to statistically model the relationships between levels
of urinary PAH analytes and the corresponding partic-
ulate polycyclic aromatic compound (P-PAC) meas-
urements in air and dermal patch samples from these
20 asphalt-exposed workers. This analysis compares
urinary analytes that may be useful biomarkers of ex-
posure to particulate PAHs among asphalt-exposed
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workers and further delineates the differences between
air samples and dermal patch samples as measures of
exposure to P-PACs. These results should aid in the
design of future studies to assess exposures to partic-
ulate PAHs in asphalt emissions for both hazard con-
trol and epidemiologic investigations.
METHODS
Subjects and air and urine measurements
Twenty male road pavers, all residing in the
Greater Boston area of the USA, were included in
this study. Workers were recruited with informed
consent according to a protocol approved for the
protection of human subjects. Information about
smoking habits and body size were obtained by ques-
tionnaire.
Starting at the beginning of the workweek, daily
air samples and dermal patch samples were collected
from each worker over three consecutive days.
Personal air measurements of PACs were obtained
according to National Institute for Occupational
Safety and Health (NIOSH) Method 5506 (NIOSH,
1998), using a personal sampling pump operating
at 2 l min1 to draw air through a Teflon filter (for
airborne P-PACs [aP-PACs]) followed by a XAD-2
sorbent tube for vapor polycyclic aromatic com-
pounds (V-PACs). Levels of P-PACs on dermal patch
samples (dP-PACs) were measured using a method
described by Jongeneelen et al. (1988) and VanRooij
et al. (1993), with minor modifications. A soft poly-
propylene filter was attached to an exposure pad to
create a dermal patch with an effective surface area
of 8.71 cm2. Using an adhesive backing, the dermal
patch was attached to the underside of each wrist
(the average of measured PAC levels on the left
and right wrists were used here). Levels of PACs in
air and dermal patch samples were analyzed using
liquid extraction coupled with high-pressure liquid
chromatography as described previously (McClean
et al., 2004a,b). The limits of detection (LOD) for to-
tal airborne PACs (V-PACs þ aP-PACs) and dP-PACs
were 0.2 lg m3 and 38 ng cm2, respectively
(McClean et al., 2004a). Method precision was eval-
uated using the intraclass correlation coefficients
(ICCs) determined from the analysis of replicate
samples. The ICCs were 0.96 for V-PACs (based on
eight replicate samples), 0.97 for aP-PACs (based
on 20 replicate samples), and 0.93 for dP-PACs
(based on 78 replicate samples), indicating that assay
variability was minimal (7% of the total variability
in sample measurements).
Urine samples were collected from all workers be-
fore work (morning), after work (postshift), and at
bedtime of each workday. Morning samples col-
lected on the first day of the workweek (after
a work-free weekend) were treated as baseline sam-
ples for each subject. Each morning sample,
collected on a subsequent workday, was treated as
the final observation for the previous workday. All
urine samples were collected in sterilized polypro-
pylene containers and stored at 20C for up to 7
years prior to analysis. Urinary creatinine concentra-
tions were determined using a colorimetric procedure
(Sigma, 1984). Concentrations of urinary Nap and
Phe (U-Nap and U-Phe, respectively) were deter-
mined using head space-solid-phase microextraction
coupled with gas chromatography–mass spectrome-
try (Waidyanatha et al., 2003; Sobus et al., 2009b).
The estimated LOD for both U-Nap and U-Phe was
0.40 ng l1 and the estimated coefficients of variation
(CVs) were 0.25 and 0.26, respectively (Sobus et al.,
2009b). Levels of 1- and 2-hydroxynaphthalene
(1- and 2-OH-Nap), 1-, 2-, 3-, 4-, and 9-hydroxyphe-
nanthrene (1-, 2-, 3-, 4-, and 9-OH-Phe), and 1-
hydroxypyrene (1-OH-Pyr) were determined using
solid-phase extraction coupled with liquid chroma-
tography–tandem mass spectrometry (Onyemauwa
et al., 2009). The limits of quantitation (LOQs) for
these analytes were as follows: 10 ng l1 for 1-OH-
Nap; 1.0 ng l1 for 2-OH-Nap; 2.0 ng l1 for
(2 þ 3)-OH-Phe (these isomers could not be chro-
matographically separated and were quantified to-
gether); and 5.0 ng l1 for 1-, 4-, and 9-OH-Phe
and 1-OH-Pyr (Onyemauwa et al., 2009). The esti-
mated CVs for these analytes ranged from 0.053 to
0.27 (Onyemauwa et al., 2009). In this investigation,
we consider the summed values of these monohy-
droxylated metabolites, such that ‘OH-Nap’ is the
sum of 1- and 2-hydroxynaphthalene, ‘OH-Phe’ is
the sum of 1-, 2-, 3-, 4-, and 9-hydroxyphenanthrene,
and ‘OH-Pyr’ is 1-hydroxypyrene.
Statistical analyses
All statistical tests were performed using SAS
statistical software (v. 9.1, SAS Institute, Cary,
NC, USA). Measurements of PACs in air and dermal
patch samples and urinary analyte levels were
evaluated after natural log transformation to satisfy
normality assumptions and to remove heteroscedas-
ticity. Considering the repeated measures study
design, linear mixed-effects models were used (Proc
MIXED) to evaluate exposure–biomarker relation-
ships. Correlation coefficients for exposure data were
determined according to Hamlett et al. (2003).
In preliminary analyses of the exposure measure-
ments, levels of aP-PACs and V-PACs were found to
be highly correlated (r 5 0.92, P-value ,0.0001)
whereas levels of aP-PACs and dP-PACs were essen-
tially uncorrelated (r 5 0.32, P-value 5 0.2). Thus,
to remove problems related to collinearity in statisti-
cal models, and for ease of interpretation, we used on-
ly aP-PACs and dP-PACs in our full mixed models. By
focusing upon the larger (four rings to six rings) carci-
nogenic PAHs that were common to both aP-PACs
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and dP-PACs (Herrick et al., 2007), we were able to
directly compare P-PAC levels in air and dermal patch
samples. (Very similar results were obtained when
V-PACs were used instead of aP-PACs in statistical
models).
Variations in urine dilution for the 20 workers were
first evaluated using a mixed-effects model with cre-
atinine as the response variable and the period of
sample collection (i.e. dummy variables for postshift,
bedtime, or morning) as the predictor variables. We
then included creatinine as in independent variable
in our full mixed-effects models to allow for
adjustments on covariates as well as the dependent
variables (Barr et al., 2005).
In our full mixed-effects models, postshift, bed-
time, and morning urinary levels were individually
regressed on the corresponding measurements of
aP-PACs and dP-PACs, along with covariates. The
following numbers of observations were available
for the different sampling times: U-Nap and U-Phe
models included 51 postshift, 50 bedtime, and 48
morning measurements, while OH-Nap, OH-Phe,
and OH-Pyr models included 49 postshift, 48 bed-
time, and 46 morning measurements (six samples
could not be analyzed due to insufficient urine vol-
ume). Baseline urine samples were not included in
the full mixed-effects models because they did not
have corresponding measurements of aP-PACs and
dP-PACs. For measurements of dP-PACs, McClean
et al. (2004a) defined the LOD as three times the
standard deviation of field blank values. Using this
criterion, 30% of dP-PAC levels used in this analy-
sis were below the LOD. However, because values
were reported for these observations, we used the re-
ported levels in our analyses and did not impute val-
ues below the LOQ.
The full mixed-effects model for an exposure–
biomarker relationship at the hth sampling time






5 b0h þb1CREATININEhij þ b2aP
PACshij þ b3dP  PACshijþb4DAYhijþ b5HOURhij
þ b6AGEi þ b7BMIi þ b8SMOKEi þ bhi þ ehij
for j 5 1, 2, . . . , nhi measurements of the ith
individual at the hth sampling time;
for i 5 1, 2, . . . , 20 individuals;
for h 5 1, 2, or 3;
where Xhij represents the analyte concentration for
the jth measurement of the ith individual and Yhij is
the natural logarithm of the individual measurement
Xhij. The coefficient b0h represents the intercept for
the hth sampling time. The coefficients b1–b8 repre-
sent the coefficients for fixed effects, which include:
CREATININEhij [creatinine concentration (g l
1) for
the jth measurement of the ith individual at the hth
sampling time]; aP-PACshij (ng m
3) and dP-PACshij
(ng cm2) which correspond to the jth air and dermal
patch measurements, respectively, for the ith individ-
ual at the hth sampling time; DAYhij and HOURhij
(hour: postshift 5 0 h; bedtime and morning values
equal elapsed hours since postshift sample) for the
jth measurement of the ith individual at the hth sam-
pling time; and AGEi, BMIi, and SMOKEi which
represent the ith subject’s age (years), body mass in-
dex (kg m2), and smoking status (nonsmoker 5 0),
respectively.
In this full model, bhi and ehij are independent ran-
dom variables; bhi represents the random effect for
the ith individual at the hth sampling time and ehij
represents the random error for the jth measurement
of the ith individual at the hth sampling time. It is as-
sumed that bhi and ehij are normally distributed with




senting the between-person and within-person com-




respectively, for sampling time h. Linear mixed-
effects models were constructed using restricted
maximum likelihood estimates of variance compo-
nents. Fixed effects were retained in the models at
a significance level of a 5 0.10, using manual back-
wards stepwise elimination. Bayesian Information
Criterion (BIC) values were used to select between
competing models. Compound symmetry covariance
matrices were used; these generally yielded the low-
est BIC diagnostic values compared to those from
homogeneous autoregressive and heterogeneous au-
toregressive matrices. Observations with missing val-
ues (i.e. air or dermal patch measurement, urinary
analyte measurement, or significant covariate) were
not included in the final models.
Linear mixed-effects models including only b0h,
bhi, and ehij were also constructed for each urinary
analyte. The estimate of r2Yh from each null model
(no additional fixed effects), designated r̂2Yhnull, was
used along with the estimate of r2Yh from each full
model (including significant fixed effects), desig-
nated r̂2Yhfull, to calculate the percent of the variance




)/r̂2Yhnull]  100 5 % explained.
RESULTS
Summary statistics for urinary analytes, P-PACs,
and covariates
Summary statistics for the urinary analytes (i.e. U-
Nap, U-Phe, OH-Nap, OH-Phe, and OH-Pyr), P-PAC
measurements (aP-PACs and dP-PACs), and covari-
ates (CREATININE, BMI, AGE, HOUR, and
SMOKE) are listed in Table 1. The long period of
sample storage (7 years) did not appreciably affect
our urinary analyte measurements, based on a com-
parison [n 5 194 common observations (including
baseline measurements)] of our OH-Pyr measure-
ments [geometric mean (GM) 5 1130 ng l1] to ear-
lier OH-Pyr measurements (GM 5 1100 ng l1)
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(McClean et al., 2004b). The correlation coefficient
for the paired OH-Pyr measurements from these
two studies was 0.89 (P-value , 0.0001), and a re-
gression coefficient of 1.02 (standard error 5
0.044) was observed when OH-Pyr measurements
from the current study were regressed on those from
the original study in log scale. Additional descriptive
statistics for the observations of U-Nap, U-Phe, OH-
Nap, OH-Phe, OH-Pyr, and PACs (dP-PACs and total
airborne PACs) have been reported elsewhere
(McClean et al., 2004a,b; Sobus et al., 2009a).
Effect of period of sample collection on urinary
creatinine levels
The results of the mixed-effects model with creat-
inine as the response variable and the period of sam-
ple collection (i.e. dummy variables for postshift,
bedtime, or morning) as the predictor variables
showed a significant effect of the period of sample
collection (P-value , 0.0001) on creatinine levels.
The highest creatinine levels were observed in post-
shift samples (mean 5 1.92 g l1), followed by bed-
time samples (mean 5 1.53 g l1), and then morning
samples (mean 5 1.37 g l1). These changes in uri-
nary creatinine levels are consistent with dehydration
of the workers during hot works shifts.
Mixed-effects models for postshift urine samples
Table 2 shows the final models for urinary analytes
in postshift samples. Levels of aP-PACs, dP-PACs,
and CREATININE were significant predictors of lev-
els of U-Nap, U-Phe, OH-Phe, and OH-Pyr, and BMI
was a significant predictor OH-Pyr. The levels of aP-
PACs, dP-PACs, and CREATININE collectively ex-
plained 66, 54, 42, and 41% of the variability in
levels of OH-Phe, U-Nap, U-Phe, and OH-Pyr, re-
spectively. When CREATININE was removed from
the models, aP-PACs and dP-PACs explained 53,
47, 37, and 35% of the variability in levels of OH-
Phe, U-Nap, U-Phe, and OH-Pyr, respectively. Con-
versely, when aP-PACs and dP-PACs were removed
from the models, CREATININE explained 13, 8, 6,
and 5% of the variability in levels of OH-Phe, U-
Nap, U-Phe, and OH-Pyr, respectively. This indicates
much weaker effects of CREATININE on analyte
levels than those of aP-PACs and dP-PACs in post-
shift urine. After adjusting for CREATININE,
aP-PACs, and dP-PACs, a significant effect of BMI
was observed on levels of OH-Pyr only. The negative
regression coefficient suggests that OH-Pyr levels
were lower in individuals with higher BMIs. Interest-
ingly, the model for OH-Nap levels was quite differ-
ent from those for all other analytes in postshift urine.
For OH-Nap, aP-PACs and dP-PACs were not signif-
icant predictors, and the final model included only
CREATININE, DAY, AGE, and SMOKE. Together,
these variables explained 74% of the postshift
variability in OH-Nap levels.
Table 2 shows, for each analyte, the estimated
between-person and within-person (log scale)
Table 1. Summary statistics (ranges and percentiles) for dependent and independent variables included in linear mixed-effects
models
n Minimum 25th 50th 75th Maximum
Dependent variablesa
U-Nap 149 8.33 27.2 55.8 92.8 528
U-Phe 149 0.62 15.0 40.0 78.2 336
OH-Nap 143 638 6350 14000 27600 138000
OH-Phe 143 335 2310 5000 8670 27300
OH-Pyr 143 17.0 578 1340 2650 13800
Independent variables
CREATININE (g l1) 149 0.14 1.15 1.57 2.06 3.36
aP-PACs (ng m3) 55 40.6 1380 2460 6580 34900
dP-PACs (ng cm2) 56 0.26 31.3 112 202 723
BMI (kg m2) 20 21.5 24.1 28.8 29.8 40.7
AGE (years) 20 21 33 45 53 60
HOUR (h)b
Postshift 51 0 0 0 0 0
Bedtime 50 2.50 5.00 6.09 7.83 14.3
Morning 48 11.8 14.8 15.3 16.7 18.6
SMOKE
No 15 NA NA NA NA NA
Yes 5 NA NA NA NA NA
n, number of observations; NA, not applicable.
aConcentration reported in ng l1.
bPostshift samples assigned values of 0; bedtime and morning values equal elapsed hours since postshift sample.
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spectively, along with corresponding values of k̂, rep-
resenting the estimated ratio of the within-person
variance component to the between-person variance
component (i.e. k̂ 5 r̂2wYh /r̂
2
bYh
). For U-Phe, r̂2bYh 5
0 indicating that all of the between-person variation
in this biomarker was explained by the significant
fixed effects, namely, aP-PACs, dP-PACs, and CRE-
ATININE. For U-Nap and OH-Pyr, after adjusting
for significant fixed effects, r̂2wYh was greater than
r̂2bYh , as shown by k̂ values of 2.23 and 1.29, respec-
tively. Values of r̂2bYhand r̂
2
wYh
were similar for OH-
Phe ðk̂ 5 0:881Þ, whereas r̂2wYh was considerably
smaller than r̂2bYh for OH-Nap ðk̂ 5 0:483Þ.
Mixed-effects models for bedtime urine samples.
Table 3 shows the final models for analytes in bed-
time urine samples. In these samples, OH-Phe was
the only analyte significantly affected by the expo-
sure variables, aP-PACs and dP-PACs, as well as
CREATININE. These combined effects explained
56% of OH-Phe variability. When CREATININE
was considered as the only fixed effect, it explained
22% of the variability in OH-Phe levels. When aP-
PACs and dP-PACs were considered as predictors
of OH-Phe without CREATININE, they explained
23% of OH-Phe variability. Thus, in bedtime sam-
ples, the exposure variables (aP-PACs and dP-PACs)
and CREATININE contributed equally to the levels
of OH-Phe and were the only significant determi-
nants of OH-Phe levels.
As with postshift samples, OH-Nap levels in bed-
time samples were highly affected by CREATININE
and SMOKE (explaining 65% of the variability in
OH-Nap) but not by aP-PACs and dP-PACs. For
OH-Pyr, U-Nap, and U-Phe, significant effects of
CREATININE and dP-PACs were observed, together
explaining 50, 30, and 30% of the respective analyte
variability. When included in the models without
other fixed effects, CREATININE explained 25, 15,
and 14% of the variability in OH-Pyr, U-Phe, and
U-Nap levels, respectively. When CREATININE
was removed from each model, dP-PACs explained
15, 12, and 11% of the variability in OH-Pyr,
U-Nap, and U-Phe levels, respectively. After adjust-
ing for dP-PACs and CREATININE, a moderately
Table 2. Results from linear mixed-effects models evaluating postshift urinary analyte levels





















































DAY NS NS 0.159
(0.051)
0.005 NS NS
BMI NS NS NS NS 0.072
(0.029)
0.02
AGE NS NS 0.016
(0.008)
0.05 NS NS


























k 2.23 NA 0.483 0.881 1.29
OH-Nap, sum of monohydroxylated metabolites of naphthalene [ln(ng l1)]; OH-Phe, sum of monohydroxylated metabolites of
phenanthrene [ln(ng l1)]; OH-Pyr, 1-hydroxypyrene [ln(ng l1)]; SE, standard error; CREATININE, creatinine concentration
(g l1); aP-PACs, air concentration of particulate polycyclic aromatic compounds [ln(ng m3)]; dP-PACs, dermal patch
concentration of particulate polycyclic aromatic compounds [ln(ng cm2)]; NA, not applicable; NS, not significant; BMI, body
mass index (kg m2); ref., reference group; U-Nap, urinary naphthalene [ln(ng l1)]; U-Phe, urinary phenanthrene [ln(ng l1)];
r2bY , between-subject variance component; r
2
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significant effect of SMOKE on U-Phe was observed
(P-value 5 0.07). When included in the model, the
combined effects of CREATININE, dP-PACs, and
SMOKE explained 36% of variability in U-Phe
levels.
Results from the final models for bedtime urine
samples showed that all analytes except U-Phe
ðk̂ 5 1:13Þ had k̂ values ,1 (U-Nap 5 0.528; OH-
Nap 5 0.698; OH-Phe 5 0.604; OH-Pyr 5 0.483),
indicating greater between-person variability com-
pared to within-person variability at bedtime.
Mixed-effects models for morning urine samples
Model results for morning samples are shown in
Table 4. Only the levels of OH-Phe were signifi-
cantly affected by aP-PACs and dP-PACs, as well
as CREATININE; together, these three variables
explained 65% of the variability in morning OH-
Phe levels. CREATININE alone explained 38% of
the variability in OH-Phe levels while aP-PACs
and dP-PACs jointly explained 25% of OH-Phe
variability.
For U-Nap and OH-Pyr, dP-PACs (but not aP-
PACs) and CREATININE were significantly associ-
ated with analyte levels, together explaining 36 and
35% of the variability in OH-Pyr and U-Nap levels,
respectively. When dP-PACs were removed from
the models, CREATININE alone explained 20 and
28% of the variability in OH-Pyr and U-Nap levels,
respectively. When dP-PACs were solely consid-
ered, 7 and 1% of the variability in OH-Pyr and
U-Nap levels was explained, respectively. After ad-
justing for CREATININE and dP-PACs, a significant
negative BMI effect was observed for OH-Pyr. In
total, the effects of CREATININE, dP-PACs, and
BMI explained 46% of the variability in OH-Pyr
levels. Levels of dP-PACs and aP-PACs from the
previous workday were not significant determinants
for either OH-Nap or U-Phe. In fact, CREATININE
and DAY were the only significant determinants for
U-Phe, explaining 33% of the variability, and CRE-
ATININE, DAY, and SMOKE were the only signif-
icant determinants for OH-Nap, together explaining
61% of the variability.
In morning urine samples, more variability in OH-
Pyr levels was observed between subjects than was
observed within subjects ðk̂ 5 0:744Þ. Estimates
of k were close to one for U-Nap and OH-Phe
Table 3. Results from linear mixed-effects models evaluating bedtime urinary analyte levels















































DAY NS NS NS NS NS
HOUR NS NS NS NS NS
BMI NS NS NS NS NS
AGE NS NS NS NS NS
































k 0.528 1.13 0.698 0.604 0.483
OH-Nap, sum of monohydroxylated metabolites of naphthalene [ln(ng l1)]; OH-Phe, sum of monohydroxylated metabolites of
phenanthrene [ln(ng l1)]; OH-Pyr, 1-hydroxypyrene [ln(ng l1)]; SE, standard error; U-Nap, urinary naphthalene [ln(ng l1)];
U-Phe, urinary phenanthrene [ln(ng l1)]; BMI, body mass index (kg m2); CREATININE, creatinine concentration (g l1);
aP-PACs, air concentration of particulate polycyclic aromatic compounds [ln(ng m3)]; dP-PACs, dermal patch concentration
of particulate polycyclic aromatic compounds [ln(ng cm2)]; NA, not applicable; NS, not significant; ref., reference group;
r2bY , between-subject variance component; r
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(k̂ 5 1.06 and 0.961, respectively) and were .1 for
U-Phe and OH-Nap (k̂ 5 3.31 and 2.60, respec-
tively). This indicates comparatively larger within-
person variability than between-person variability
for U-Phe and OH-Nap compared to U-Nap, OH-
Nap and OH-Pyr in morning urine samples.
DISCUSSION
The purpose of this investigation was to evaluate
and compare urinary PAH analytes as biomarkers
of exposure to PAHs among asphalt-exposed workers
and to further delineate the differences between air
samples and dermal patch samples as measures of ex-
posure to P-PACs. From our expanded analysis of
urinary PAH biomarkers in these paving workers,
we found that aP-PACs and dP-PACs were each
strongly associated with the urinary PAH analytes
(see Table 2), but were essentially uncorrelated with
each other (r 5 0.32, P-value 5 0.2). We conclude
that air and dermal patch measurements contributed
independently to the levels of the urinary biomarkers,
and that aP-PACs and dP-PACs provide reasonable
measures of particulate PAH exposure by both routes
at the time of urine collection.
Figure 1 shows the percentages of the variances
of the various urinary analytes that were explained
by aP-PACs and dP-PACs in postshift, bedtime,
and morning samples. The variables aP-PACs and
dP-PACs explained much more of the variability
of biomarker levels in postshift urine samples (up
to 53%), compared to bedtime (up to 23%) and
morning (up to 25%) samples. In postshift samples,
the strongest associations with aP-PACs and dP-
PACs were observed for OH-Phe (53% of explained
variance) followed by U-Nap (47%), U-Phe (37%),
and OH-Pyr (35%). In bedtime and morning urine
samples, aP-PACs and dP-PACs were much weaker
predictors of urinary biomarker levels than they
were in postshift urine samples. Nonetheless, levels
of OH-Phe were significantly associated with both
aP-PACs and dP-PACs in bedtime and morning
samples, levels of U-Nap and OH-Pyr were signifi-
cantly associated with dP-PACs (but not aP-PACs)
in bedtime and morning samples, and levels of
U-Phe were associated with dP-PACs in bedtime
Table 4. Results from linear mixed-effects models evaluating morning urinary analyte levels


















































HOUR NS NS NS NS NS
BMI NS NS NS NS 0.094
(0.041)
0.03
AGE NS NS NS NS NS




























k 1.06 3.31 2.60 0.961 0.744
OH-Nap, sum of monohydroxylated metabolites of naphthalene [ln(ng l1)]; OH-Phe, sum of monohydroxylated metabolites of
phenanthrene [ln(ng l1)]; OH-Pyr, 1-hydroxypyrene [ln(ng l1)]; U-Nap, urinary naphthalene [ln(ng l1)]; U-Phe, urinary
phenanthrene [ln(ng l1)]; SE, standard error; CREATININE, creatinine concentration (g l1); aP-PACs, air concentration of
particulate polycyclic aromatic compounds [ln(ng m3)]; dP-PACs, dermal patch concentration of particulate polycyclic aromatic
compounds [ln(ng cm2)]; NA, not applicable; NS, not significant; ref., reference group; r2bY , between-subject variance




bY ); BMI, body mass index (kg m
2).
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(but not morning) samples (Tables 3 and 4). The
consistent influence of dP-PACs on levels of PAH
biomarkers in bedtime urine and morning urine
samples suggest that dermal contact with Nap,
Phe, and Pyr persisted well into the evening after
a given work shift. Thus, results from our models
are consistent with the earlier findings of McClean
et al. (2004b), based upon measurements of Pyr
and OH-Pyr, and also suggest that levels of U-
Nap, U-Phe, OH-Phe, as well as OH-Pyr, are suit-
able biomarkers of PAH exposure emanating from
hot mix asphalt via both inhalation and dermal
contact.
The fact that these PAH biomarkers were more
highly associated with exposure variables in postshift
urine samples, compared to bedtime and morning
samples, indicates that Nap, Phe, and Pyr were rap-
idly absorbed, metabolized, and eliminated from
the body during and immediately following the work
shift. Since aP-PACs, dP-PACs, and the urinary bio-
markers were measured over three consecutive days,
we included a workday effect into our models (i.e.
DAY) to test the possibility that biomarker levels ac-
cumulated over the workweek. After adjusting for
aP-PACs, dP-PACs, and other significant covariates,
no significant workday effects were observed for
U-Nap, OH-Phe, or OH-Pyr. A significant positive
workday effect was observed for U-Phe in morning
samples only. While this indicates a linear increase
in morning U-Phe levels for 3 days, our overall re-
sults reinforce the conclusion that these urinary ana-
lytes primarily reflect PAH exposures on the current
day, and thus would be regarded as short-term
biomarkers of exposure (Rappaport and Kupper,
2008). A significant positive workday effect was also
observed for OH-Nap in postshift samples and morn-
ing samples. However, because the variables aP-
PACs and dP-PACs were not included in the final
models (most likely due to the confounding effects
of smoking), it is difficult to interpret the observed
workday effect for OH-Nap.
In addition to assessing workday effects, we used
a fixed effect for time in h postshift (i.e. HOUR) be-
cause bedtime and morning collection times varied
from day to day and from person to person. The me-
dian collection time for bedtime samples was 6.09 h
[range: 2.50–14.3 h (see Table 1)] and the median
collection time for morning samples was 15.3 h
[range: 11.8–18.6 h (see Table 1)]. Results from each
model showed no significant effect of HOUR on an-
alyte levels. This indicates that, after making adjust-
ments for exposure levels and other covariates, subtle
variations in sampling times did not affect urinary
analyte levels.
In preliminary models, urinary creatinine concen-
trations were significantly affected by the period of
sample collection (i.e. postshift, bedtime, or morn-
ing). This finding indicates that urine volumes varied
considerably within and between the road pavers un-
der investigation, perhaps reflecting a diurnal excre-
tion pattern (Boeniger et al., 1993) as well as the
dehydration of workers during the hot work shifts.
In the full mixed-effects models, levels of urinary
creatinine (CREATININE) were significant predic-
tors of all urinary analytes. The positive regression
coefficient in each model (Tables 2, 3, and 4) indi-
cates increased analyte levels with increased creati-
nine levels. Figure 2 shows the percent of each
analyte’s variance explained by CREATININE in
urine collected postshift, at bedtime, and in the morn-
ing following exposure. Overall, U-Nap and U-Phe
were less affected by CREATININE than OH-Nap
and OH-Phe; this would be expected because unme-
tabolized organic compounds tend to enter urine via
diffusion from blood rather than via glomerular filtra-
tion in the kidney, the latter mechanism being
responsible for elimination of polar metabolites
(Boeniger et al., 1993). However, Fig. 2 also shows
an increase in the strength of association between uri-
nary analytes and CREATININE from postshift to
morning. This trend runs counter to that observed be-
tween P-PACs and urinary analytes (Fig. 1), indicat-





























Fig. 1. Percentage of urinary analyte variance collectively
explained by aP-PACs (measurements of particulate PACs in
air samples) and dP-PACs (measurements of particulate PACs
on dermal patch samples).
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analyte variability in postshift samples, and that urine
dilution dominates the variability in morning sam-
ples. This result is easily explained considering the
short biological half-lives of these urinary analytes
and has important implications for biomonitoring
studies in which first morning void samples are often
used to infer chemical exposures on the previous day.
In postshift, bedtime, and morning samples, neither
aP-PACs nor dP-PACs were significantly associated
with levels of OH-Nap. However, smoking status
(i.e. SMOKE) was a highly significant determinant
of OH-Nap levels, as has been observed elsewhere
(Serdar et al., 2003a,b; Väänänen et al., 2006; Buratti
et al., 2007). We determined that smoking and signif-
icant covariates (CREATININE, DAY, and AGE)
were able to explain 74, 65, and 61% of the variability
in OH-Nap levels in postshift, bedtime, and morning
samples, respectively. However, smoking status was
not a significant determinant of U-Nap levels in post-
shift, bedtime, or morning samples. This result was
somewhat surprising given that Nap is present in cig-
arette smoke (Rustemeier et al., 2002). However, our
results for U-Nap corroborates those from previous
studies where smoking status had little effect on U-
Nap levels, particularly in moderately to highly ex-
posed workers (Serdar et al., 2003a; Waidyanatha
et al., 2003). Serdar et al. (2004) showed that, at low
Nap exposure levels, smokers produced higher OH-
Nap levels than nonsmokers, and, at high Nap exposure
levels, smokers produced lower OH-Nap levels than
nonsmokers and speculated that these results reflected
induction of microsomal epoxide hydrolase enzymes
by cigarette smoke at low Nap exposure levels. A sim-
ilar mechanism could have influenced OH-Nap levels
in this study. We also observed a significant smoking
effect on U-Phe levels in bedtime samples. Consider-
ing the lack of a smoking effect for U-Phe levels in
postshift samples, the observed elevation of U-Phe lev-
els at bedtime due to smoking seems to be relatively
modest compared to those of aP-PACs and dP-PACs.
We observed a significant negative BMI effect on
OH-Pyr levels (the only biomarker affected), as pre-
viously reported by McClean et al. (2004b), based
upon independent measurements of OH-Pyr in these
same 20 subjects. This observation may indicate in-
creased storage of Pyr in adipose tissue with elevated
exposures, thereby limiting the amount of Pyr in the
systemic circulation that is available for metabolism.
Tables 2–4 list estimated values of the within-
subject and between-subject variance components
obtained from the mixed-effects models of each uri-
nary biomarker, as well as the corresponding esti-
mated variance ratio in each case. Lin et al. (2005)
used values of k̂ to choose between air measurements
and biomarker measurements in selecting the least
biasing surrogate for exposure in estimating the slope
of an exposure–response relationship. In the current
study, we can use k̂ values to choose among postshift,
bedtime, and morning urine samples to find the min-
imally biased biomarker of exposure for an epidemi-
ological investigation. Interestingly, k̂ values for
each of the biomarkers, save OH-Nap (which was
affected primarily by smoking), were minimal in
bedtime urine samples (see Tables 2–4). Indeed, for
U-Nap (k̂ 5 0.53), OH-Phe (k̂ 5 0.60), and
OH-Pyr (k̂ 5 0.48), the variance ratios were in the
range of 0.5, which were much smaller than those
for the same analytes in postshift urine samples
where values of k̂ 5 2.2, 0.88, and 1.3, respectively.
In light of the earlier discussion concerning the pos-
sibility that these biomarkers reflect continued ef-
fects of dP-PACs, this finding opens the possibility
that bedtime measurements of these biomarkers
could be useful in investigating dermal exposures
to PAH. This conjecture will require further experi-
mental confirmation.
Finally, we use our results to suggest the most
promising urinary PAH biomarker for studies of
asphalt-exposed workers. Urinary OH-Pyr is a widely
used PAH biomarker in occupational studies
(Jongeneelen, 2001), and we observed significant
associations between P-PAHs (as measured by
aP-PACs and dP-PACs) and OH-Pyr levels in our
subjects. This result was expected because Pyr,
a four-ring PAH, is often abundant in measurements
of PM from asphalt and combustion sources. Some-
what more surprising were the significant associa-
tions between Nap and Phe biomarkers (namely
U-Nap, U-Phe, and OH-Phe) and P-PAC measure-
ments. Naphthalene, a two-ring PAH, occurs almost
exclusively in the gas phase, whereas Phe, a three-
ring PAH, is partitioned between the gas and partic-
ulate phases. Our results suggest that these abundant
two-ring and three-ring PAHs may also be good sur-
rogates for particulate exposures stemming from hot
asphalt sources. Moreover, the results from our post-
shift models indicate stronger associations between
levels of U-Nap, U-Phe, and OH-Phe and the
P-PAC levels in air and dermal patch samples than
the corresponding associations for OH-Pyr. Overall,
we consider OH-Phe as the most promising candidate
biomarker for evaluating particulate asphalt expo-
sures. We do not recommend use of OH-Nap as a bio-
marker of exposure to particulate asphalt emissions,
due to the apparent confounding by smoking.
FUNDING
National Institute of Environmental Health Scien-
ces (training grant T32ES07018, research grant
P42ES05948, and center grant P30ES10126).
Acknowledgements—Disclaimer—The content is solely the re-
sponsibility of the authors and does not necessarily represent
the official view of the National Institute of Environmental
Health Sciences or the National Institutes of Health.
570 J. R. Sobus et al.
REFERENCES
Barr DB, Wilder LC, Caudill SP et al. (2005) Urinary creati-
nine concentrations in the U.S. population: implications for
urinary biologic monitoring measurements. Environ Health
Perspect; 113: 192–200.
Boeniger MF, Lowry LK, Rosenberg J. (1993) Interpretation of
urine results used to assess chemical exposure with emphasis
on creatinine adjustments: a review. Am Ind Hyg Assoc J;
54: 615–27.
Boffetta P, Jourenkova N, Gustavsson P. (1997) Cancer risk
from occupational and environmental exposure to polycy-
clic aromatic hydrocarbons. Cancer Causes Control; 8:
444–72.
Boffetta P, Burstyn I, Partanen Tet al. (2003a) Cancer mortality
among European asphalt workers: an international epidemi-
ological study. I. Results of the analysis based on job titles.
Am J Ind Med; 43: 18–27.
Boffetta P, Burstyn I, Partanen T et al. (2003b) Cancer mortal-
ity among European asphalt workers: an international epide-
miological study. II. Exposure to bitumen fume and other
agents. Am J Ind Med; 43: 28–39.
Buratti M, Campo L, Fustinoni S et al. (2007) Urinary hydrox-
ylated metabolites of polycyclic aromatic hydrocarbons as
biomarkers of exposure in asphalt workers. Biomarkers;
12: 221–39.
Burstyn I, Kromhout H. (2000) Are the members of a paving
crew uniformly exposed to bitumen fume, organic vapor,
and benzo(a)pyrene? Risk Anal; 20: 653–63.
Burstyn I, Boffetta P, Burr GA et al. (2002) Validity of empir-
ical models of exposure in asphalt paving. Occup Environ
Med; 59: 620–4.
Burstyn I, Boffetta P, Kauppinen Tet al. (2003) Performance of
different exposure assessment approaches in a study of bitu-
men fume exposure and lung cancer mortality. Am J Ind
Med; 43: 40–8.
Burstyn I, Kromhout H, Johansen C et al. (2007) Bladder can-
cer incidence and exposure to polycyclic aromatic hydrocar-
bons among asphalt pavers. Occup Environ Med; 64: 520–6.
Campo L, Addario L, Buratti M et al. (2006a) Biological mon-
itoring of exposure to polycyclic aromatic hydrocarbons by
determination of unmetabolized compounds in urine. Toxi-
col Lett; 162: 132–8.
Campo L, Buratti M, Fustinoni S et al. (2006b) Evaluation of
exposure to PAHs in asphalt workers by environmental and
biological monitoring. Ann N Y Acad Sci; 1076: 405–20.
Chiazze L, Jr, Watkins DK, Amsel J. (1991) Asphalt and risk of
cancer in man. Br J Ind Med; 48: 538–42.
Hamlett A, Ryan L, Serrano-Trespalacios P et al. (2003) Mixed
models for assessing correlation in the presence of replica-
tion. J Air Waste Manag Assoc; 53: 442–50.
Herrick RF, McClean MD, Meeker JD et al. (2007) Physical
and chemical characterization of asphalt (bitumen) paving
exposures. J Occup Environ Hyg; 4 (Suppl 1): 209–16.
Hooiveld M, Burstyn I, Kromhout H et al. (2002) Quantitative
risk assessment for lung cancer after exposure to bitumen
fume. Toxicol Ind Health; 18: 417–24.
IARC. (1987) ‘‘Overall evaluations of carcinogenicity, an up-
dating of IARC monographs.’’ IARC monographs on the
evaluation of the carcinogenic risk of chemicals to humans.
Vols. 1–42, Suppl 7 Lyon, France: IARC.
Jongeneelen FJ. (2001) Benchmark guideline for urinary 1-
hydroxypyrene as biomarker of occupational exposure to
polycyclic aromatic hydrocarbons. Ann Occup Hyg; 45:
3–13.
Jongeneelen FJ, Scheepers PT, Groenendijk A et al. (1988) Air-
borne concentrations, skin contamination, and urinary
metabolite excretion of polycyclic aromatic hydrocarbons
among paving workers exposed to coal tar derived road tars.
Am Ind Hyg Assoc J; 49: 600–7.
Lin YS, Kupper LL, Rappaport SM. (2005) Air samples versus bi-
omarkers for epidemiology. Occup Environ Med; 62: 750–60.
McClean MD, Rinehart RD, Ngo L et al. (2004a) Inhalation
and dermal exposure among asphalt paving workers. Ann
Occup Hyg; 48: 663–71.
McClean MD, Rinehart RD, Ngo L et al. (2004b) Urinary 1-
hydroxypyrene and polycyclic aromatic hydrocarbon exposure
among asphalt paving workers. Ann Occup Hyg; 48: 565–78.
NIOSH. (1998) ‘‘Polycyclic aromatic hydrocarbons by HPLC:
method 5506.’’ In Schlecht PC and O’Connor PE, editors.
NIOSH manual of analytical methods. 4th edn. Cincinnati,
OH: US Department of Health and Human Services.
NIOSH. (2000) ‘‘Health effects of occupational exposure to
asphalt’’. Cincinnati: OH: US Department of Health and
Human Services.
Onyemauwa F, Rappaport SM, Sobus JR et al. (2009) Using
liquid chromatography-tandem mass spectrometry to quan-
tify monohydroxylated metabolites of polycyclic aromatic
hydrocarbons in urine. J Chromatogr B Analyt Technol Bi-
omed Life Sci; 877: 1117–25.
Partanen T, Boffetta P. (1994) Cancer risk in asphalt workers
and roofers: review and meta-analysis of epidemiologic
studies. Am J Ind Med; 26: 721–40.
Randem BG, Burstyn I, Langard S et al. (2004) Cancer inci-
dence of Nordic asphalt workers. Scand J Work Environ
Health; 30: 350–5.
Rappaport SM, Kupper LL. (2008) Quantitative exposure as-
sessment. 1st edn. El Cerrito, CA: Stephen Rappaport.
Rustemeier K, Stabbert R, Haussmann HJ et al. (2002) Evalu-
ation of the potential effects of ingredients added to ciga-
rettes. Part 2: chemical composition of mainstream smoke.
Food Chem Toxicol; 40: 93–104.
Serdar B, Egeghy PP, Waidyanatha S et al. (2003a) Urinary
biomarkers of exposure to jet fuel (JP-8). Environ Health
Perspect; 111: 1760–4.
Serdar B, Waidyanatha S, Zheng Y et al. (2003b) Simultaneous
determination of urinary 1- and 2-naphthols, 3- and
9-phenanthrols, and 1-pyrenol in coke oven workers. Bio-
markers; 8: 93–109.
Serdar B, Egeghy PP, Gibson R et al. (2004) Dose-dependent
production of urinary naphthols among workers exposed to
jet fuel (JP-8). Am J Ind Med; 46: 234–44.
Sigma. (1984) Creatinine: quantitative, colorimetric determina-
tion in serum, plasma or urine at 500 nm. Procedure no. 555.
St Louis, MO: Sigma Chemicals Co.
Sobus JR, McClean MD, Herrick RF et al. (2009a) Investiga-
tion of PAH biomarkers in the urine of workers exposed to
hot asphalt. Ann Occup Hyg; in press.
Sobus JR, Waidyanatha S, McClean MD et al. (2009b) Urinary
naphthalene and phenanthrene as biomarkers of occupa-
tional exposure to polycyclic aromatic hydrocarbons. Occup
Environ Med; 66: 99–104.
VanRooij JG, De Roos JH, Bodelier-Bade MM et al. (1993)
Absorption of polycyclic aromatic hydrocarbons through hu-
man skin: differences between anatomical sites and individ-
uals. J Toxicol Environ Health; 38: 355–68.
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